BioSpace News Archive

TCR2 Therapeutics Inc. today announced positive interim results from the ongoing Phase 1 portion of the gavo-cel Phase 1/2 clinical trial for mesothelin-expressing solid tumors.

Oral presentation at ESMO Annual Congress 2021 - featured in a late-breaking abstract - reports efficacy and safety of BALVERSA® in combination with a PD-1 inhibitor in bladder cancer

PROS is a spectrum of rare disorders caused by PIK3CA mutations and is characterized by atypical, visible overgrowths and anomalies in blood vessels, the lymphatic system and other tissues

Navidea Biopharmaceuticals, Inc. announced that on September 14, 2021, at a meeting of the Board of Directors of the Company that followed the Company’s 2021 Annual Meeting of Stockholders, S. Kathryn Rouan, Ph.D. retired as Chair of the Board and as a director, and Claudine Bruck, Ph.D. retired as a director, both effective immediately.

Innate Pharma SA today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on September 17, 2021.

Gain Therapeutics, Inc. today announced that Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Catalyst Pharmaceuticals, Inc. today announced that Patrick J. McEnany, Catalyst’s Chief Executive Officer and Steven Miller, Ph.D., Chief Scientific Officer /COO, will participate at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Aerovate Therapeutics, Inc., a clinical stage biopharmaceutical company focused on developing drugs that meaningfully improve the lives of patients with rare cardiopulmonary disease, announced it has been added to the Russell 2000® Index, effective after the market’s close, following the recent Russell US Indexes annual reconstitution.

Vaccinex, Inc. today announced that Elizabeth Evans, PhD, Chief Operating Officer, is scheduled to present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit.

NS Pharma, Inc. announced today an electronic poster presentation on long-term efficacy and safety data (interim analysis at 109 weeks) from the open-label extension (up to 192 weeks) of a Phase 2 study of VILTEPSO® (viltolarsen) injection at the World Muscle Society 2021 Virtual Conference being held September 20–24.